Medical Developments International

18 November 2026

ASX ANNOUNCEMENT

Interim CEO Remuneration Update

Medical Developments International (ASX: MVP) refers to its announcement dated 15 October 2026 and the appointment of Anita James as Interim Chief Executive Officer in addition to her role as Chief Financial Officer.

MVP today announced that revised remuneration arrangements have been agreed as follows. There has been no change to Ms. Jame's short or long-term incentive percentages as disclosed in the most recent Annual Report.

Term	Detail
Effective date	15 October 2026
Total Fixed Remuneration (TFR)	$130,000 per annum increase, pro rated while in the interim role. This takes Ms. James' annual TFR to $571,778 while in the Interim CEO role.
Notice	6 months. This is an increase from 3 months previously.
Retention	$110,500 payable on 30 June 2027. $110,500 payable on 31 December 2027

Authorised for release by the Board of Directors.

Enquiries:

Tara Eaton
Company Secretary
+61 (3) 9547 1888

About Medical Developments International Ltd

MVP is an Australian company delivering emergency medical solutions, including pain relief and respiratory products, and is dedicated to improving patient outcomes. The Company manufactures Penthrox®, a non-opioid trauma & emergency pain relief product. It is approved in Australia for pain relief in settings such as hospitals, ambulance services and short procedures, in accordance with the approved Product Information.